GlassScriptPhysician profile
Timothy Young Chou
NPI 1588669469
$5,382.21
in general payments reported to CMS, 2019-2025
22 companies · $1,327 in 2025
The $1,327 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $88.37 · 2021: $200 · 2022: $735 · 2023: $1,471 · 2024: $1,278 · 2025: $1,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,075.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $1,552.66 | 2022-2025 | Acthar |
| Oyster Point Pharma, INC. | $941.20 | 2022-2025 | Tyrvaya |
| Alcon Vision LLC | $357.51 | 2019-2025 | Simbrinza, Eysuvis, Clareon |
| Sun Pharmaceutical Industries INC. | $348.84 | 2020-2025 | Cequa |
| Abbvie INC. | $336.76 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Novartis Pharmaceuticals Corporation | $273.47 | 2019-2023 | |
| Biotissue Holdings INC. | $209.11 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $205.16 | 2024-2025 | Purified Cortrophin Gel, Iluvien, Yutiq |
| Dompe US, INC. | $195.04 | 2019-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $193.37 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $183.62 | 2024-2025 | Xdemvy |
| Allergan, INC. | $94.73 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $93.61 | 2019-2020 | |
| Harrow Eye, LLC | $77.68 | 2024 | Vevye |
| Ocular Therapeutix, INC. | $67.56 | 2024-2025 | Dextenza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $61.22 | 2023 | Kxl1b-Ce-Marked Kxlsystem, Kxl System (Not Refurbished) |
| Shire North American Group INC | $45.60 | 2019 | |
| Eyevance Pharmaceuticals LLC | $44.15 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $30.13 | 2021 | |
| Sight Sciences, INC. | $29.08 | 2023 | Tearcare System |
| Apellis Pharmaceuticals, INC. | $23.68 | 2025 | Syfovre |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Chou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.